Oral Administration of the Growth Hormone Secretagogue MK-677 Increases Markers of Bone Turnover in Healthy and Functionally Impaired Elderly Adults.

MLA

Murphy, M. G., et al. “Oral Administration of the Growth Hormone Secretagogue MK-677 Increases Markers of Bone Turnover in Healthy and Functionally Impaired Elderly Adults.” Journal of Bone & Mineral Research, vol. 14, no. 7, July 1999, pp. 1182–88. EBSCOhost, https://doi.org/10.1359/jbmr.1999.14.7.1182.

APA

Murphy, M. G., Bach, M. A., Plotkin, D., Bolognese, J., Ng, J., Krupa, D., Cerchio, K., & Gertz, B. J. (1999). Oral Administration of the Growth Hormone Secretagogue MK-677 Increases Markers of Bone Turnover in Healthy and Functionally Impaired Elderly Adults. Journal of Bone & Mineral Research, 14(7), 1182–1188. https://doi.org/10.1359/jbmr.1999.14.7.1182

Chicago

Murphy, M. G., M. A. Bach, D. Plotkin, J. Bolognese, J. Ng, D. Krupa, K. Cerchio, and B. J. Gertz. 1999. “Oral Administration of the Growth Hormone Secretagogue MK-677 Increases Markers of Bone Turnover in Healthy and Functionally Impaired Elderly Adults.” Journal of Bone & Mineral Research 14 (7): 1182–88. doi:10.1359/jbmr.1999.14.7.1182.